Novartis Ag

Signal Pharmaceuticals, Inc.

Johanne Renaud

Hans Allgeier

Manuel Koller

Joachim Nozulak

Henri Mattes

Wolfgang Froestl

David Orain

Philipp Floersheim

Yves Auberson

David Carcache

Jörg Kallen

Christel Guibourdenche

Shripad S Bhagwat

Marc Gerspacher

Sven Weiler

Eva Altmann

Jeffrey A McKie

Martin Missbach

Leo Widler

Rene Beerli

Silvio Ofner

Nicolas Soldermann

Vittorio Rasetti

A compound of formula (1): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein Rand Rare as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy

The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.

Quinazoline derivatives

N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide

A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives

Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands

Benzopyranone Compounds having the following structure: 

Benzopyranone compounds, compositions thereof, and methods of treatment therewith

Benzopyrazone compounds, compositions thereof, and methods of treatment therewith

Growing community of inventors

Basel, Switzerland

Johanne Renaud